- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Amgen acquires rights to Neupogen, Neulasta in 100 markets from Roche
- ROUNDTABLE: Pharmacy’s future in sync with technology
THOUSAND OAKS, Calif. Several lots of two drugs used to treat anemia are being recalled due to possible contamination.
Amgen said Friday that it was voluntarily recalling certain lots of Epogen and Procrit (epoetin alfa) from distributors, wholesalers, healthcare providers and pharmacies as a precaution due to the possible presence of extremely thin and barely visible glass flakes known as lamellae that result from an interaction between the drugs and the glass vials used to store them.
The drugs are used to treat anemia resulting from chemotherapy, kidney failure and HIV therapy.